Related Experiment Videos
Alpha-interferon and its effects on signal transduction pathways
Michele Caraglia1, Monica Marra, Girolamo Pelaia
1Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, Naples, Italy. michele.caraglia@unina2.it
Journal of Cellular Physiology
|September 25, 2004
Summary
Interferon-alpha (IFNalpha) regulates cancer cell growth via apoptosis, but resistance occurs. Targeting the epidermal growth factor (EGF)-mediated Ras/Erk pathway may enhance IFNalpha
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interferon-alpha (IFNalpha) is a recombinant cytokine used in cancer therapy, regulating cell growth and differentiation.
- While IFNalpha can induce apoptosis in cancer cells, its precise mechanisms and tumor resistance pathways are not fully understood.
- IFNalpha's role as a post-translational regulator of tissue transglutaminase (tTG) and its impact on apoptosis are areas of ongoing research.
Purpose of the Study:
- To review the established signal transducer and activator of transcription (STAT)-dependent mechanisms of IFNalpha action.
- To discuss the role of stress-dependent kinase pathways and apoptosis in IFNalpha's anti-cancer effects.
- To explore novel mechanisms of tumor resistance to IFNalpha, particularly the epidermal growth factor (EGF)-mediated Ras/extracellular signal regulated kinase (Erk) pathway.
Main Methods:
- Review of existing literature on IFNalpha signaling and apoptosis.
- Analysis of data on stress-dependent kinase pathways and their correlation with apoptosis.
- Investigation of IFNalpha's effect on tissue transglutaminase (tTG) degradation.
- In vitro studies examining tumor resistance mechanisms, including JAK-STAT alterations and EGF-mediated signaling.
Main Results:
- IFNalpha utilizes STAT-dependent pathways and can trigger stress-dependent kinases, promoting apoptosis.
- IFNalpha modulates tTG levels through post-translational regulation of its proteasome-dependent degradation.
- Tumor resistance to IFNalpha can involve alterations in JAK-STAT signaling.
- A novel resistance mechanism involves EGF-mediated Ras/Erk signaling, protecting cells from IFNalpha-induced apoptosis.
Conclusions:
- IFNalpha's anti-cancer effects are mediated through complex signaling pathways, including STAT and stress-kinases, leading to apoptosis.
- Understanding IFNalpha's regulation of tTG offers new insights into its therapeutic actions.
- The EGF-mediated Ras/Erk pathway represents a significant mechanism of tumor resistance to IFNalpha.
- Disrupting the Ras/Erk pathway holds potential for enhancing IFNalpha's anti-tumor efficacy in resistant cancers.